Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer

American Surgeon

Volumn 75, Issue 9, 2009, Pages 785-789

  Kansakar, Erina ^a   Chang, Yeon Jeen ^a   Mehrabi, Massoud ^a   Mittal, Vijay ^a  

^a PROVIDENCE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; VASCULOTROPIN A; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; BIOSYNTHESIS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; THYROID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 70349782454     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER website, 2009.
2. Ron E. Thyroid cancer. In: Schottenfeld D, Fraumeni Jr. JF, eds.. Cancer Epidemiology and Prevention. New York: Oxford University Press, 1996, pp 1000-1021
3. Cady B, Sedgwick CE, Meissner WA, et al. Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810-820 (Pubitemid 9163606)
4. Parkin DM, Whelan SL, Ferlay JL, et al. Cancer Incidence in Five Continents, Vol VII, IARC Sci. Publ. No.143. Lyon, France: International Agency for Research on Cancer and International association of Cancer Registries, 1997.
5. Blot WJ, Le Marchand L, Boice JD, Henderson BE. Thyroid cancer in the Pacific. J. Natl. Cancer Inst. (Bethesda) 1997;89:90-91
6. Waterhouse J, Muir C, Shanmugaratnam K, Powell J, Cancer Incidence in Five Continents, Vol IV. Lyon France: IARC Scientific Publications, 1982, pp 185-198.
7. Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factors in vascular development. Curr Top Microbiol Immunol 1999;237:133-158 (Pubitemid 28554862)
8. Eriksson U, Alitalo K. Structure expression and receptor binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999;237:47-51.
9. Ferrar N. Vascular endothelial growth factor: molecular and biologic aspects. Curr Top Microbiol Immunol 1999;237:47-51.
10. Neufield G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22. (Pubitemid 29038270)
11. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998;17:241-248 (Pubitemid 28391959)
12. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) associated with malignancy in human thyroid cells and cell lines. Oncogene 1995;11:1569-1579
13. Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: Strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999;161:41-49 (Pubitemid 29170190)
14. Cancer Staging Manual AJCC, 6th Ed. New York: Springer, 2002, pp 77-87.
15. Van Hoeven KH, Menendez-Botet CJ. Estrogen and progesterone receptor content in human thyroid disease. Am J Clin Pathol 1993;99-2:175-181
16. Miki H, Oshimo K, Inoue H, et al. Sex hormone receptors in human thyroid tissues. Cancer 1990;66:1759-1762 (Pubitemid 20381213)
17. Chen CG, Vlantis AC, van Hasselt CA. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 2008;8:367-377
18. Zeng Q, Chen G, Vlantis A, et al. The contributions of oestrogen receptor isoforms to development of papillary and anaplastic thyroid carcinomas. J Pathol 2008;214:425-433 (Pubitemid 351350536)
19. Tavangar SM, Monajemzadeh M, Larijani B, Haghpanah V. Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Med J 2007;48:744-747 (Pubitemid 351235329)
20. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Report based on 53,856 cases of thyroid carcinoma cases treated in the US, 1985-1995. Cancer 1998;83:2638-2648
21. Ain KB. Anaplastic thyroid carcinoma: behaviour, biology and therapeutic approaches. Thyroid 1998;8:715-726
22. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15:78-83.
23. Fenton C, Patel A, Dinauer C, et al. The expression of vascular endothelial growth factor and the type 1 vascular growth factor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000;10:349-357 (Pubitemid 30256865)